Cargando…
Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas
BACKGROUND: Central nervous system lymphomas (CNSL) is a devastating disease. Currently, a confirmatory biopsy is required prior to treatment. OBJECTIVE: Our investigation aims to prove the feasibility of a minimally-invasive diagnostic approach for the molecular characterization of CNSL. METHODS: T...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397454/ https://www.ncbi.nlm.nih.gov/pubmed/30823914 http://dx.doi.org/10.1186/s12885-019-5394-x |
_version_ | 1783399418783858688 |
---|---|
author | Hickmann, Anne-Katrin Frick, Maximilian Hadaschik, Dirk Battke, Florian Bittl, Markus Ganslandt, Oliver Biskup, Saskia Döcker, Dennis |
author_facet | Hickmann, Anne-Katrin Frick, Maximilian Hadaschik, Dirk Battke, Florian Bittl, Markus Ganslandt, Oliver Biskup, Saskia Döcker, Dennis |
author_sort | Hickmann, Anne-Katrin |
collection | PubMed |
description | BACKGROUND: Central nervous system lymphomas (CNSL) is a devastating disease. Currently, a confirmatory biopsy is required prior to treatment. OBJECTIVE: Our investigation aims to prove the feasibility of a minimally-invasive diagnostic approach for the molecular characterization of CNSL. METHODS: Tissue biopsies from 6 patients with suspected CNSL were analyzed using a 649gene next-generation sequencing (NGS) tumor panel (tumor vs. reference tissue (EDTA-blood)). The individual somatic mutation pattern was used as a basis for the digital PCR analyzing circulating tumor DNA (ctDNA) from plasma and cerebrospinal fluid (CSF) samples, identifying one selected tumor mutation during this first step of the feasibility investigation. RESULTS: NGS-analysis of biopsy tissue revealed a specific somatic mutation pattern in all confirmed lymphoma samples (n = 5, NGS-sensitivity 100%) and none in the sample identified as normal brain tissue (NGS-specificity 100%). cfDNA-extraction was dependent on the extraction-kit used and feasible in 3 samples, in all of which somatic mutations were detectable (100%). Analysis of CSF-derived cfDNA was superior to plasma-derived cfDNA and routine microscopic analysis (lymphoma cells: n = 2, 40%). One patient showed a divergent molecular pattern, typical of Burkitt-Lymphoma (HIV+, serologic evidence of EBV-infection). Lumbar puncture was tolerated without complications, whereas biopsy caused 3 hemorrhages. CONCLUSIONS: Our investigation provides evidence that analysis of cfDNA in central nervous system tumors is feasible using the described protocol. Molecular characterization of CNSL could be achieved by analysis of CSF-derived cfDNA. Knowledge of a tumor’s specific mutation pattern may allow initiation of targeted therapies, treatment surveillance and could lead to minimally-invasive diagnostics in the future. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-5394-x) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6397454 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-63974542019-03-13 Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas Hickmann, Anne-Katrin Frick, Maximilian Hadaschik, Dirk Battke, Florian Bittl, Markus Ganslandt, Oliver Biskup, Saskia Döcker, Dennis BMC Cancer Case Report BACKGROUND: Central nervous system lymphomas (CNSL) is a devastating disease. Currently, a confirmatory biopsy is required prior to treatment. OBJECTIVE: Our investigation aims to prove the feasibility of a minimally-invasive diagnostic approach for the molecular characterization of CNSL. METHODS: Tissue biopsies from 6 patients with suspected CNSL were analyzed using a 649gene next-generation sequencing (NGS) tumor panel (tumor vs. reference tissue (EDTA-blood)). The individual somatic mutation pattern was used as a basis for the digital PCR analyzing circulating tumor DNA (ctDNA) from plasma and cerebrospinal fluid (CSF) samples, identifying one selected tumor mutation during this first step of the feasibility investigation. RESULTS: NGS-analysis of biopsy tissue revealed a specific somatic mutation pattern in all confirmed lymphoma samples (n = 5, NGS-sensitivity 100%) and none in the sample identified as normal brain tissue (NGS-specificity 100%). cfDNA-extraction was dependent on the extraction-kit used and feasible in 3 samples, in all of which somatic mutations were detectable (100%). Analysis of CSF-derived cfDNA was superior to plasma-derived cfDNA and routine microscopic analysis (lymphoma cells: n = 2, 40%). One patient showed a divergent molecular pattern, typical of Burkitt-Lymphoma (HIV+, serologic evidence of EBV-infection). Lumbar puncture was tolerated without complications, whereas biopsy caused 3 hemorrhages. CONCLUSIONS: Our investigation provides evidence that analysis of cfDNA in central nervous system tumors is feasible using the described protocol. Molecular characterization of CNSL could be achieved by analysis of CSF-derived cfDNA. Knowledge of a tumor’s specific mutation pattern may allow initiation of targeted therapies, treatment surveillance and could lead to minimally-invasive diagnostics in the future. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-5394-x) contains supplementary material, which is available to authorized users. BioMed Central 2019-03-01 /pmc/articles/PMC6397454/ /pubmed/30823914 http://dx.doi.org/10.1186/s12885-019-5394-x Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Case Report Hickmann, Anne-Katrin Frick, Maximilian Hadaschik, Dirk Battke, Florian Bittl, Markus Ganslandt, Oliver Biskup, Saskia Döcker, Dennis Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas |
title | Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas |
title_full | Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas |
title_fullStr | Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas |
title_full_unstemmed | Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas |
title_short | Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas |
title_sort | molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor dna in patients with central nervous system lymphomas |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397454/ https://www.ncbi.nlm.nih.gov/pubmed/30823914 http://dx.doi.org/10.1186/s12885-019-5394-x |
work_keys_str_mv | AT hickmannannekatrin moleculartumoranalysisandliquidbiopsyafeasibilityinvestigationanalyzingcirculatingtumordnainpatientswithcentralnervoussystemlymphomas AT frickmaximilian moleculartumoranalysisandliquidbiopsyafeasibilityinvestigationanalyzingcirculatingtumordnainpatientswithcentralnervoussystemlymphomas AT hadaschikdirk moleculartumoranalysisandliquidbiopsyafeasibilityinvestigationanalyzingcirculatingtumordnainpatientswithcentralnervoussystemlymphomas AT battkeflorian moleculartumoranalysisandliquidbiopsyafeasibilityinvestigationanalyzingcirculatingtumordnainpatientswithcentralnervoussystemlymphomas AT bittlmarkus moleculartumoranalysisandliquidbiopsyafeasibilityinvestigationanalyzingcirculatingtumordnainpatientswithcentralnervoussystemlymphomas AT ganslandtoliver moleculartumoranalysisandliquidbiopsyafeasibilityinvestigationanalyzingcirculatingtumordnainpatientswithcentralnervoussystemlymphomas AT biskupsaskia moleculartumoranalysisandliquidbiopsyafeasibilityinvestigationanalyzingcirculatingtumordnainpatientswithcentralnervoussystemlymphomas AT dockerdennis moleculartumoranalysisandliquidbiopsyafeasibilityinvestigationanalyzingcirculatingtumordnainpatientswithcentralnervoussystemlymphomas |